Related Experiment Video
Updated: Aug 5, 2026

10:33
Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Update on imaging biomarkers in uveitis
1Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada.
Current Opinion in Ophthalmology
|August 2, 2026
Summary
Quantitative imaging biomarkers for uveitis show promise but require further validation. Consensus frameworks and AI are advancing standardized assessment, shifting bottlenecks to validation and clinical integration.
Area of Science:
- Ophthalmology
- Medical Imaging
- Inflammatory Diseases
Background:
- Uveitis diagnosis and monitoring rely heavily on imaging, but standardized, clinically useful biomarkers are lacking.
- Current imaging techniques provide valuable data but often lack disease-specific precision and validation for clinical decision-making.
Purpose of the Study:
- To assess the clinical utility of current uveitis imaging biomarkers.
- To identify imaging biomarkers that are incompletely validated.
- To explore the role of consensus frameworks and artificial intelligence in standardizing uveitis assessment.
Main Methods:
- Review of quantitative optical coherence tomography (OCT) and OCT angiography (OCTA) metrics.
- Analysis of anterior segment OCT particle-size analysis and OCTA vessel density.
- Evaluation of choroidal vascularity index and multimodal uveitis (MUV) international taskforce consensus sets.
- Assessment of artificial intelligence (AI) applications in uveitis imaging.
Main Results:
- Quantitative OCT and OCTA metrics demonstrate disease-specific precision.
- Anterior segment OCT particle-size analysis effectively differentiates inflammatory cells from pigment.
- OCTA vessel density tracks chronic changes in specific conditions like birdshot chorioretinopathy.
- The MUV taskforce established consensus imaging sets for white dot syndromes.
- AI shows proof-of-concept but requires larger datasets and prospective validation.
Conclusions:
- Most uveitis imaging biomarkers are disease-specific and require further validation.
- Quantitative imaging and international consensus frameworks are improving biomarker utility.
- The primary challenges have shifted from image acquisition to validation, standardization, and clinical outcome integration.
